Drugs / EOS006215
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06877533 | Apr → Jul 2025 | — | iTeos Therapeutics | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EOS006215 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06877533 ↗ |
| Modality | Monoclonal antibody | “a fully human monoclonal antibody” NCT06877533 ↗ |
| Target | TREM2 | “binds to the triggering receptor expressed on myeloid cells 2 (TREM2)” NCT06877533 ↗ |